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Background: The aims of this study were to generate a comprehensive potentially inappropriate medi-
cation (PIM) list applicable for Korean elderly based on the international PIM lists (Beers, Screening Tool
for Older Person's Prescriptions, and PRISCUS), and to determine the PIM prevalence rate in the elderly
who utilized long-term care services.
Methods: We generated a list of drug ingredients included in all the three criteria, and also the current
Korean national formulary list. Twenty-six drug ingredients belonging to seven drug classes were ﬁnally
selected. A two-round Delphi survey consisting of 20 experts was conducted to make a consensus on the
PIM criteria applicable to Korean elderly. Individual questions regarding PIM criteria were answered
using a 5-point Likert scale. The PIM prevalence rate in elderly was analyzed using the National Health
Insurance claims data and the Long-term Care Beneﬁt claims data over a 6-month period (from July 2011
to December 2011).
Results: All 26 drug ingredients were determined to be PIMs for Korean elderly. The prevalence rate of
PIM in elderly under long-term care was 41.4% (98,158/237,285 individuals). Benzodiazepines were the
most prevalent PIM drug class (28.9%), followed by ﬁrst generation antihistamines (26.9%). The use of
nonsteroidal anti-inﬂammatory drugs and tricyclic antidepressants were 9.3% and 6.4% of total in-
dividuals, respectively.
Conclusion: The comprehensive PIM list may be helpful for clinical practitioners to optimize drug choices
for their elderly patients. A relatively high PIM prevalence in the elderly suggests that efﬁcient strategies
should be designed to reduce PIM in elderly populations in long-term care settings.
Copyright © 2015, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Inappropriate prescribing in the elderly is associated with
negative outcomes including adverse drug events, increased hos-
pitalization, and resource utilization1e4. Accordingly, avoiding
inappropriate drug use is an important and effective strategy in
reducing medication-related problems and reducing health care
costs5. Several explicit criteria to screen potentially inappropriate
medication (PIM) use in the elderly were used to evaluates of interest to declare and no
uate School of Clinical Phar-
eong-dong 689, Bundang-gu,
a.
tric Emergency & Critical Care Meinappropriate drug use status. Beers' criteria developed in the
United States is the most frequently used6, but concerns about the
generalizability to other populations are increasing7. Thus, other
criteria such as the Canadian criteria8, Screening Tool for Older
Person's Prescriptions (STOPP), and PRISCUS (Latin for old and
venerable elderly) have been generated to apply to other regions. A
new set of explicit criteria called STOPPwas validated in Ireland and
Britain and has been used in other European countries9, and the
PRISCUS list was speciﬁcally designed for its applicability in Ger-
many10. We recognize the necessities of localized explicit criteria
that reﬂect a country- or region-speciﬁc health care system, cir-
cumstances, cultures, drug market (especially reimbursement
policy), and practice patterns. In Korea, Beers' criteria or STOPP
criteria have been used in medicinal and pharmacological re-
searches for identifying PIM11e13, but they have not been veriﬁeddicine. Published by Elsevier Taiwan LLC. All rights reserved.
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Korean settings yet.
Recently, the importance of medication use management in the
elderly has been magniﬁed since national long-term care services
for the elderly were incorporated into the National Health Insur-
ance (NHI) scheme since July 2008 in Korea. It is well known how
important medication management in the elderly population at a
higher risk of adverse drug events is. As one of the medication
management strategies, reduction of PIM prevalence is crucial. In
this regard, the generation of explicit criteria to evaluate PIM use in
elderly should come ﬁrst.
The aims of this study were to generate a comprehensive PIM
list applicable for Korean elderly based on the three international
PIM lists (Beers, STOPP, and PRISCUS), and to determine PIM
prevalence rates in the elderlywho utilized long-term care services.
2. Materials and Methods
2.1. Study design: A Delphi survey
To generate a PIM list speciﬁcally applicable to Korean elderly,
two-rounds Delphi surveys with a number of questions were un-
dertaken from July 9, 2013 to August 13, 2013. The Delphi method,
as an expert consensus process, provides a systematic way to
converge the expertise of people working in a particular area and
gives guidance that is readily applicable to a particular context14.
Three international PIM lists (Beers 2012 version, STOPP 2008
version, and PRISCUS 2010 version) often used worldwide, were
used for drafting a PIM list for the Delphi survey in this study.
Pharmacist researchers extracted a total of 31 intersectional drug
ingredients which were included in all the three published PIM
criteria as the abovementioned. Among them, ﬁve drug ingredients
(doxepin, oxazepam, thioridazine, trimipramine, and zaleplon)
which were not included in the current Korean national drug for-
mulary list were excluded (Figure 1). Finally, 26 ingredients from
seven drug classes were selected as PIM candidates (Table 1). Del-
phi panel experts were asked to rate their agreement levels on the
inclusion of those 26 ingredients individually in the PIM list forFigure 1. Flow chart of the study. PIM ¼ potentially inappropriate medication;
STOPP ¼ Screening Tool for Older Person’s Prescriptions.Korean elderly with given clinical conditions/diseases. Rating
scores were given according to a 5-point Likert scale: 1 ¼ strongly
agreed; 2 ¼ agreed; 3 ¼ equivocal; 4 ¼ disagreed; and 5 ¼ strongly
disagreed. They were allowed to answer “unable to decide” if it was
too difﬁcult to rate a score. They were also asked to describe the
reasons for their ratings, if possible. Survey questionnaires were
collected via e-mail from the panel participants for two sequential
rounds. A summary of ratings by panelists was fed back to all the
panel participants after Round 1. Panel members were allowed to
change their ﬁrst ratings in Round 2. This process resulted in a list of
statements that had substantial consensus in its ratings.
2.2. Delphi participants
A total of 20 panel experts were invited to participate and
complete the survey questionnaires in both Rounds 1 and 2. The
panel size was a convenient sample number that was likely to yield
stable results in this study. With a Delphi method, participants act
as a panel of experts making private and independent ratings of
agreement with a series of statements15. Expert panel participants
in this study consisted of 14 physicians and six pharmacists who
had experience in a wide range of specialties across the internal
medicine, mental health, neurology, gerontology, preventive
medicine, urology, family medicine, rheumatology, and clinical
pharmacy ﬁelds, and who have been working in general hospitals
or universities as clinical practitioners and/or researchers (Table 2).
2.3. Consensus validation of localized PIM list
After Round 2was completed, the survey results were presented
as mean scores of agreement levels for individual questions which
were reported by 20 panel participants. A mean score of 3.0 was
used as the cut-off point to be agreed on, including the drug in the
localized PIM list for Korean elderly. Any items > 3.0 points were
not eligible for the localized PIM list.
2.4. Data sources and data analysis
The NHI claims data and Long-term Care Beneﬁt claims data
were used to identify PIM exposure in the elderly. The adminis-
trative NHI claims data included information on patients' de-
mographics (sex, age), clinical conditions (disease diagnosis ICD-10
codes), health care service utilization including inpatient and
outpatient settings, drug prescriptions, and health careTable 1
Drugs included in the national formulary list and listed as potentially inappropriate
medication for elderly in the Beers, STOPP, and PRISCUS criteria.
Class of drug
ingredients
Name of drug ingredients No. of
ingredients
TCAs Amitriptyline, clomipramine, imipramine 3
Benzodiazepines  Short- & intermediate-acting: alprazolam,
clorazepam, triazolam
 Long-acting: chlorazepate, chlordiazepoxide,
diazepam, ﬂurazepam
7
Neuroleptic
drugs
Perphenazine, clozapine, haloperidol,
olanzapine
4
1st generation
antihistamines
Chlorpheniramine, clemastine, doxylamine,
triprolidine
4
Antimuscarinic
drugs
Oxybutynin 1
NSAIDs Indomethacin, piroxicam, ketoprofen,
meloxicam
4
Alpha-blockers Prazosin, doxazosin, terazosin 3
Total 26
NSAIDs ¼ nonsteroidal anti-inﬂammatory drugs; STOPP ¼ Screening Tool for Older
Person's Prescriptions; TCAs ¼ tricyclic antidepressants.
Table 2
Specialty of Delphi Panel survey participants.
Specialty No. of participants
Internal medicine 4
Mental health 2
Neurology 1
Gerontology 2
Preventive medicine 2
Urology 1
Family medicine 1
Rheumatology 1
Clinical pharmacy 6
Total 20
S.O. Kim et al.138expenditures, and the Long-term Care Beneﬁt claims data included
information on patients' daily living activities and long-term care
service utilization. Elderly patients who were aged  65 years and
utilized long-term care services at either a nursing facility or home
were enrolled to investigate PIM prevalence for the 6-month period
(from July 1, 2013 to December 31, 2011). Based on the PIM list
validated by the two-rounds Delphi panel survey the above
mentioned overall PIM prevalence rate and prevalence per drug
class were analyzed. Clinical conditions designated on the PIM
criteria were determined using ICD-10 disease codes reported on
the NHI claims data. SAS version 9.2 (SAS Institute Inc. Cary, NC)
was used for data analysis. This study was approved by the Insti-
tutional Review Board of the NHI service (No. 2013-03).3. Results
3.1. Consensus result
The mean scores for individual questionnaire items that 20
panel participants answered in Rounds 1 and 2 are shown inTable 3
Panel survey results: tricyclic antidepressants, benzodiazepines, and neuroleptic drugs.
Drug class Ingredient PIM criter
B ¼ Beers
S ¼ STOPP
TCAs Amitriptyline, Clomipramine, Imipramine Dementia
Glaucoma
Cardiac co
Constipat
Chronic c
TCAs with
TCAs with
Syncope o
Delirium
A history
Benzodiazepines (short- & intermediate-acting) Alprazolam,
Clorazepam, Triazolam,
(long-acting) Chlorazepate, Chlordiazepoxide,
Diazepam, Flurazepam
Long-term
long-actin
Drugs tha
(1 fall in
A history
Delirium
Dementia
Neuroleptic drugs Perphenazine, Clozapine, Haloperidol, Olanzapine Long-term
Long-term
Parkinson
Drugs tha
(1 fall in
A history
Syncope o
Delirium
Dementia
Chronic c
PIM ¼ potentially inappropriate medication; STOPP ¼ Screening Tool for Older Person'sTables 3 and 4. All 26 drug ingredients in a given disease or clinical
condition listed as PIM candidates received < 3.0 point mean score
and resulted in inclusion in the localized PIM list for Korean elderly.3.2. Prevalence of PIM
The overall prevalence of at least one PIM was 41.4% (98,158
individuals) among a total of 237,285 elderly individuals who uti-
lized long-term care services during a 6-month period. Benzodi-
azepines were the highest prevalent drug class which 28.9% of
elderly individuals used, followed by ﬁrst generation antihista-
mines used in 26.9% of individuals. Nonsteroidal anti-inﬂammatory
drugs and tricyclic antidepressants were used in 9.3% and 6.4% of
individuals, respectively (Figure 2).4. Discussion
4.1. Consensus validation for PIM list
This study is the ﬁrst attempt to elicit a localized list of explicit
criteria for identifying PIM use, together with clinical conditions in
the Korean elderly population, through a consensus validation
process in which experts in the ﬁeld of geriatric medications
participated in. To set explicit criteria is important to identify PIMs
involving potential risks of adverse drug events that outweigh its
clinical beneﬁt, and to design effective strategies to minimize those
risks. There are very useful explicit criteria to identify PIMs which
were developed in North America and European countries16, but
they have not been validated for Asian populations. More optimized
criteria for Korean elderly is needed to precisely ﬁgure out PIM
exposures at a higher risk in local populations. In this regard, the
localized PIM list generated in this study which was consensus
validated by Delphi survey will accelerate further discussions aboutia (disease/clinical condition)
' criteria
criteria
Panel survey result
(mean score)
Round 1 Round 2
(S), Dementia & cognitive/mental impairment (B) 1.95 1.95
(S) 1.75 1.65
nductive abnormalities (S) 2.20 2.30
ion (S)
onstipation (B)
2.25 2.30
an opiate or calcium channel blocker (S) 2.25 2.35
prostatism or prior history of urinary retention (S) 1.70 1.60
r fainting (B) 1.70 1.60
(B) 1.50 1.50
of falls or fractures (B) 1.90 1.90
(i.e., >1 mo), long-acting benzodiazepines with
g metabolites (S)
1.70 1.75
t adversely affect those prone to falls
past 3 mo) (S)
of falls or fractures (B)
1.70 1.65
(B) 1.95 1.95
& cognitive/mental impairment (B) 1.84 1.85
(i.e. >1 mo) neuroleptics as long-term hypnotics (S) 2.05 2.10
neuroleptics (>1 mo) in those with parkinsonism (S)
's disease (B)
1.74 1.85
t adversely affect those prone to falls
past 3 mo) (S)
of falls or fractures (B)
1.95 1.95
r fainting (B) 1.95 1.90
(B) 2.60 2.65
& cognitive/mental impairment (B) 2.13 2.25
onstipation (B) 2.40 2.35
Prescriptions; TCAs ¼ tricyclic antidepressants.
Table 4
Panel survey results: ﬁrst generation antihistamines, antimuscarinic drugs, nonsteroidal anti-inﬂammatories, and alpha-blockers.
Drug class Ingredient PIM criteria (disease/clinical condition)
B ¼ Beers' criteria
S ¼ STOPP criteria
Panel survey result
(mean score)
Round 1 Round 2
1st generation antihistamines Chlorpheniramine, Clemastine,
Doxylamine, Triprolidine
Prolonged use (>1 wk) of ﬁrst generation antihistamines
i.e., diphenydramine, chlorpheniramine, cyclizine, promethazine (S)
1.68 1.68
Drugs that adversely affect those prone to falls (1 fall in past 3 mo) (S) 2.00 2.00
Chronic constipation (B) 2.37 2.32
Antimuscarinic drugs Oxybutynin Bladder antimuscarinic drugs with dementia (S) 1.95 1.90
Bladder antimuscarinic drugs with chronic glaucoma (S) 1.72 1.74
Bladder antimuscarinic drugs with chronic constipation (S, B) 2.05 2.00
Bladder antimuscarinic drugs with chronic prostatism (S) 1.84 1.85
NSAIDs Indomethacin, Piroxicam, Ketoprofen,
Meloxicam
NSAID with a history of peptic ulcer disease or gastrointestinal bleeding,
unless with concurrent histamine H2 receptor antagonist,
PPI or misoprostol (S)
1.68 1.68
Chronic constipation (B) 2.37 2.32
NSAID with moderate-severe hypertension (moderate: 160/100 mmHg;
severe: 180/110 mmHg) (S)
2.39 2.42
NSAID with heart failure (S, B) 1.94 1.94
Long-term use of NSAID (>3 mo) for relief of mild joint pain in
osteoarthtitis (S)
2.06 2.11
Warfarin & NSAID together (S) 1.74 1.68
NSAID with chronic renal failure (estimated glomerular ﬁltration
rate 20e50 mL/min) (S)
Poor kidney function (B)
1.38 1.35
Long-term NSAID or colchicine for chronic treatment of gout where
there is no contraindication to allopurinol (S)
2.13 2.18
Alpha-blockers Prazosin, doxazosin, terazosin Alpha-blockers in males with frequent incontinence, i.e., 1 episodes
of incontinence daily (S)
2.26 2.42
Stress or mixed urinary incontinence (loss of urine when
sneezing/coughing/ bending over/with exercise) (B)
2.05 2.16
Alpha-blockers with long-term urinary catheter in situ, i.e., >2 mo (S) 2.13 2.19
Syncope or fainting (B) 1.65 1.50
NSAID ¼ nonsteroidal anti-inﬂammatory drug; PIM ¼ potentially inappropriate medication; STOPP ¼ Screening Tool for Older Person's Prescriptions.
Inappropriate medications for the elderly in South Korea 139PIM criteria in Asian countries. The Delphi survey result revealed
overall consensus on the PIM criteria which were developed in
Western countries. Participants of the survey agreed that all the 26
ingredients for 37 diseases or clinical conditions included in the
questionnaires were inappropriate for Korean elderly. Although,
Kim et al17 developed a list of 57 PIM drugs for Korean elderly using
the Delphi survey method with a 14 expert panel, they adopted
only drug ingredients without considering clinical conditions based
on Beers criteria6,18,19, Canadian criteria8, and Zhan's classiﬁcation20
using Fialova et al's21 therapeutic classiﬁcation.
The Delphi survey method has several possible limitations.
Firstly, the Delphi method applied as a consensus validation
technique in generating PIM list allowed Delphi participants toFigure 2. Prevalence rate of potentially inappropriate medication in elderly population w
inﬂammatory drugs; PIM ¼ potentially inappropriate medication; TCAs ¼ tricyclic antidepranswer a clear-cut single score to individual questions without
considering more complex individualized clinical situations of
patients in real practices, resulting in a greater dependence on the
20 Delphi participants' opinions. Accordingly, mean scores to-
wards convergence were used to decide eligibilities of individual
criteria. This kind of iterative Delphi procedure has been used
frequently in expert consensus validations for developing inap-
propriate drug lists for elderly in other country settings6,22e24.
Secondly, 20 experts participated in the Delphi survey were all the
professors belonging to medical schools or pharmacy schools. This
may arouse concerns about a weak representativeness of the real
world of clinical practices. However, our selection was the result of
our best-efforts considering their concurrent working practices asho utilized long-term care services during 6 months. NSAIDs ¼ nonsteroidal anti-
essants.
S.O. Kim et al.140well as their reputations as well-known experts in those ﬁelds.
Thirdly, questionnaire items included in the Delphi survey were
extracted basically from other countries' criteria, which were
probably focusing on the drug products being marketed in those
countries. It meant that the drug list validated in this study did not
fully cover all the drugs available in the Korean drug market. But,
there was no available data useful for evidence-based PIM list
generation in this study. Thus, consensus validation for currently
available criteria, even though they were originated in the other
country situations, was practical at this time. Further research is
needed to strengthen this study's results through the systematic
generation of independent explicit criteria for PIM more suitable
for Asian.
4.2. PIM prevalence
An overall PIM prevalence rate of 41.4% in Korean elderly who
utilized long-term care services reported in this study seems quite
high. Recent studies reported different prevalence rates of at least
one PIM in a different country and a different setting. In Italy, the
PIM prevalence rate in hospitalized elderly patients according to
2012 version of the Beers' criteria was 23.5%25. In Spain, 37.5% of
elderly in a primary health care setting used PIM according to
original STOPP criteria26. In Australia, 40% of patients were exposed
to at least one PIM in 2005 according to Beers criteria27, and in the
UK, 26.7% of patients in a hospital setting used PIM according to
STOPP criteria28. In Brazil, 82.6% among the elderly who used drugs
daily were exposed to at least one PIM29.
There are some limitations in PIM prevalence analysis of this
study. Firstly, the NHI claims datawe used did not include sufﬁcient
information on the clinical conditions of patients, which was
necessary to properly evaluate the inappropriateness of medica-
tion. For example, we could not identify a speciﬁc event (e.g., fall
within past 3months) occurrence date, because the NHI claims data
recorded by the ICD-10 code did not include detailed information
on patients' clinical conditions. This limitation probably resulted in
the overestimation of PIM prevalence, in particular for benzodiaz-
epines, neuroleptics, and ﬁrst generation antihistamines, due to
unclear patient history of falls. In addition, we could not investigate
any possible effect of PIM on patient's health outcomes. Secondly,
the NHI claims data did not include some drug ingredients which
were not reimbursed by the NHI service, even though they are used
in the market such as doxepin, oxazepam, and thioridazine, and
which were not available in the Korean market, such as trimipr-
amine and zaleplon. This limitation might lead to the underesti-
mation of PIM prevalence rate in Korean elderly. However, the NHI
claims data including whole Korean populations are a very worthy
source for comprehending the magnitude of PIM exposures under
the NHI system. Further research to investigate an association be-
tween PIM exposures and clinical outcomes are required to
strongly support the usefulness of explicit criteria in clinical
practices.
In conclusion, the localized list of PIM criteria generated through
an expert consensus validation process in this study may help
clinical practitioners choose the optimal drug for their elderly pa-
tients. Application of the PIM criteria could reduce drug-related
adverse events and prevent subsequent health care costs. Also, it
could be used as teaching material for training medical students
and practicing doctors to encourage appropriate medication use in
caring for elderly patients and a tool for evaluating the quality of
drug prescriptions in clinical settings. A high prevalence rate of PIM
in the elderly under long-term care services reported in this study
suggests necessities of designing efﬁcient strategies for reducing
PIMs to assure drug safety together with successful treatment
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